Skip to main content
Top
Published in: Familial Cancer 3/2012

01-09-2012 | Original Article

Molecular characterization of parathyroid tumors from two patients with hereditary colorectal cancer syndromes

Authors: Adam Andreasson, Luqman Sulaiman, Sónia do Vale, João Martin Martins, Florbela Ferreira, Gabriel Miltenberger-Miltenyi, Lucas Batista, Felix Haglund, Erik Björck, Inga-Lena Nilsson, Anders Höög, Catharina Larsson, C. Christofer Juhlin

Published in: Familial Cancer | Issue 3/2012

Login to get access

Abstract

The tumor suppressor adenomatous polyposis coli (APC) has recently been implicated in parathyroid development. We here report clinical, histopathological and molecular investigations in parathyroid tumors arising in two patients; one familial adenomatous polyposis (FAP) syndrome patient carrying a constitutional APC mutation, and one Lynch syndrome patient demonstrating a germline MLH1 mutation as well as a non-classified, missense alteration of the APC gene. We sequenced the entire APC gene in tumor and constitutional DNA from both cases, assessed the levels of APC promoter 1A and 1B methylation by bisulfite Pyrosequencing analysis and performed immunohistochemistry for APC and parafibromin. In addition, copy number analysis regarding the APC gene on chromosome 5q21-22 was performed using qRT-PCR. Histopathological workup confirmed both tumors as parathyroid adenomas without signs of malignancy or atypia. No somatic mutations or copy number changes for the APC gene were discovered in the tumors; however, in both cases, the APC promoter 1A was hypermethylated while the APC promoter 1B was unmethylated. APC promoter 1B-specific mRNA and total APC mRNA levels were higher than in normal parathyroid samples. Immunohistochemical analyses revealed strong APC protein immunoreactivity and positive parafibromin expression in both parathyroid tumors. Absence of additional somatic APC mutations and copy number changes in addition to the positive APC immunoreactivity obtained suggest that the tumors arose without biallelic inactivation of the APC tumor suppressor gene. The finding of an unmethylated APC promoter 1B and high APC 1B mRNA levels could explain the maintained APC protein expression. Moreover, the findings of positive parafibromin and APC immunoreactivity as well as a low MIB-1 proliferation index and absence of histopathological features of malignancy/atypical adenoma indicate that the parathyroid adenomas arising in these patients did not harbor malignant potential.
Appendix
Available only for authorised users
Literature
1.
go back to reference DeLellis RA, Lloyd RV et al (2004) Pathology and genetics of the tumours of endocrine organs, WHO classification of tumours. IARC Press, Lyon DeLellis RA, Lloyd RV et al (2004) Pathology and genetics of the tumours of endocrine organs, WHO classification of tumours. IARC Press, Lyon
2.
go back to reference DeLellis RA, Mazzaglia P, Mangray S (2008) Primary hyperparathyroidism: a current perspective. Arch Pathol Lab Med 132:1251–1262PubMed DeLellis RA, Mazzaglia P, Mangray S (2008) Primary hyperparathyroidism: a current perspective. Arch Pathol Lab Med 132:1251–1262PubMed
3.
go back to reference Carpten JD, Robbins CM, Villablanca A, Forsberg L, Presciuttini S, Bailey-Wilson J, Simonds WF, Gillanders EM, Kennedy AM, Chen JD, Agarwal SK, Sood R, Jones MP, Moses TY, Haven C, Petillo D, Leotlela PD, Harding B, Cameron D, Pannett AA, Höög A, Heath H III, James-Newton LA, Robinson B, Zarbo RJ, Cavaco BM, Wassif W, Perrier ND, Rosen IB, Kristoffersson U, Turnpenny PD, Farnebo LO, Besser GM, Jackson CE, Morreau H, Trent JM, Thakker RV, Marx SJ, Teh BT, Larsson C, Hobbs MR (2002) HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet 32:676–680PubMedCrossRef Carpten JD, Robbins CM, Villablanca A, Forsberg L, Presciuttini S, Bailey-Wilson J, Simonds WF, Gillanders EM, Kennedy AM, Chen JD, Agarwal SK, Sood R, Jones MP, Moses TY, Haven C, Petillo D, Leotlela PD, Harding B, Cameron D, Pannett AA, Höög A, Heath H III, James-Newton LA, Robinson B, Zarbo RJ, Cavaco BM, Wassif W, Perrier ND, Rosen IB, Kristoffersson U, Turnpenny PD, Farnebo LO, Besser GM, Jackson CE, Morreau H, Trent JM, Thakker RV, Marx SJ, Teh BT, Larsson C, Hobbs MR (2002) HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet 32:676–680PubMedCrossRef
4.
go back to reference Mosimann C, Hausmann G, Basler K (2006) Parafibromin/Hyrax activates Wnt/Wg target gene transcription by direct association with beta-catenin/Armadillo. Cell 125:327–341PubMedCrossRef Mosimann C, Hausmann G, Basler K (2006) Parafibromin/Hyrax activates Wnt/Wg target gene transcription by direct association with beta-catenin/Armadillo. Cell 125:327–341PubMedCrossRef
5.
go back to reference Juhlin CC, Haglund F, Villablanca A, Forsberg L, Sandelin K, Bränström R, Larsson C, Höög A (2009) Loss of expression for the Wnt pathway components adenomatous polyposis coli and glycogen synthase kinase 3-beta in parathyroid carcinomas. Int J Oncol 34:481–492PubMed Juhlin CC, Haglund F, Villablanca A, Forsberg L, Sandelin K, Bränström R, Larsson C, Höög A (2009) Loss of expression for the Wnt pathway components adenomatous polyposis coli and glycogen synthase kinase 3-beta in parathyroid carcinomas. Int J Oncol 34:481–492PubMed
6.
go back to reference Juhlin CC, Nilsson IL, Johansson K, Haglund F, Villablanca A, Höög A, Larsson C (2010) Parafibromin and APC as screening markers for malignant potential in atypical parathyroid adenomas. Endocr Pathol 21:166–177PubMedCrossRef Juhlin CC, Nilsson IL, Johansson K, Haglund F, Villablanca A, Höög A, Larsson C (2010) Parafibromin and APC as screening markers for malignant potential in atypical parathyroid adenomas. Endocr Pathol 21:166–177PubMedCrossRef
7.
go back to reference Svedlund J, Aurén M, Sundström M, Dralle H, Akerström G, Björklund P, Westin G (2010) Aberrant WNT/β-catenin signaling in parathyroid carcinoma. Mol Cancer 9:294PubMedCrossRef Svedlund J, Aurén M, Sundström M, Dralle H, Akerström G, Björklund P, Westin G (2010) Aberrant WNT/β-catenin signaling in parathyroid carcinoma. Mol Cancer 9:294PubMedCrossRef
8.
go back to reference Juhlin CC, Kiss NB, Villablanca A, Haglund F, Nordenström J, Höög A, Larsson C (2010) Frequent promoter hypermethylation of the APC and RASSF1A tumour suppressors in parathyroid tumours. PLoS ONE 5:e9472PubMedCrossRef Juhlin CC, Kiss NB, Villablanca A, Haglund F, Nordenström J, Höög A, Larsson C (2010) Frequent promoter hypermethylation of the APC and RASSF1A tumour suppressors in parathyroid tumours. PLoS ONE 5:e9472PubMedCrossRef
9.
go back to reference Segditsas S, Sieber OM, Rowan A, Setien F, Neale K, Phillips RK, Ward R, Esteller M, Tomlinson IP (2008) Promoter hypermethylation leads to decreased APC mRNA expression in familial polyposis and sporadic colorectal tumours, but does not substitute for truncating mutations. Exp Mol Pathol 285:201–206CrossRef Segditsas S, Sieber OM, Rowan A, Setien F, Neale K, Phillips RK, Ward R, Esteller M, Tomlinson IP (2008) Promoter hypermethylation leads to decreased APC mRNA expression in familial polyposis and sporadic colorectal tumours, but does not substitute for truncating mutations. Exp Mol Pathol 285:201–206CrossRef
10.
go back to reference Hosoya K, Yamashita S, Ando T, Nakajima T, Itoh F, Ushijima T (2009) Adenomatous polyposis coli 1A is likely to be methylated as a passenger in human gastric carcinogenesis. Cancer Lett 285:182–189PubMedCrossRef Hosoya K, Yamashita S, Ando T, Nakajima T, Itoh F, Ushijima T (2009) Adenomatous polyposis coli 1A is likely to be methylated as a passenger in human gastric carcinogenesis. Cancer Lett 285:182–189PubMedCrossRef
11.
go back to reference Rohlin A, Engwall Y, Fritzell K, Göransson K, Bergsten A, Einbeigi Z, Nilbert M, Karlsson P, Björk J, Nordling M (2011) Inactivation of promoter 1B of APC causes partial gene silencing: evidence for a significant role of the promoter in regulation and causative of familial adenomatous polyposis. Oncogene (Epub ahead of print) Rohlin A, Engwall Y, Fritzell K, Göransson K, Bergsten A, Einbeigi Z, Nilbert M, Karlsson P, Björk J, Nordling M (2011) Inactivation of promoter 1B of APC causes partial gene silencing: evidence for a significant role of the promoter in regulation and causative of familial adenomatous polyposis. Oncogene (Epub ahead of print)
12.
go back to reference Worm J, Christensen C, Grønbaek K, Tulchinsky E, Guldberg P (2004) Genetic and epigenetic alterations of the APC gene in malignant melanoma. Oncogene 23:5215–5226PubMedCrossRef Worm J, Christensen C, Grønbaek K, Tulchinsky E, Guldberg P (2004) Genetic and epigenetic alterations of the APC gene in malignant melanoma. Oncogene 23:5215–5226PubMedCrossRef
13.
go back to reference Nishisho I, Nakamura Y, Miyoshi Y, Miki Y, Ando H, Horii A, Koyama K, Utsunomiya J, Baba S, Hedge P (1991) Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 253:665–669PubMedCrossRef Nishisho I, Nakamura Y, Miyoshi Y, Miki Y, Ando H, Horii A, Koyama K, Utsunomiya J, Baba S, Hedge P (1991) Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 253:665–669PubMedCrossRef
14.
go back to reference Rubinfeld B, Souza B, Albert I, Müller O, Chamberlain SH, Masiarz FR, Munemitsu S, Polakis P (1993) Association of the APC gene product with beta-catenin. Science 262:1731–1734PubMedCrossRef Rubinfeld B, Souza B, Albert I, Müller O, Chamberlain SH, Masiarz FR, Munemitsu S, Polakis P (1993) Association of the APC gene product with beta-catenin. Science 262:1731–1734PubMedCrossRef
15.
go back to reference Goss KH, Groden J (2000) Biology of the adenomatous polyposis coli tumor suppressor. J Clin Oncol 18:1967–1979PubMed Goss KH, Groden J (2000) Biology of the adenomatous polyposis coli tumor suppressor. J Clin Oncol 18:1967–1979PubMed
16.
go back to reference Nilsson IL, Zedenius J, Li Y, Ekbom A (2007) The association between primary hyperparathyroidism and malignancy. Nationwide cohort analysis on cancer incidence after parathyroidectomy. Endocr Relat Cancer 14:1–7CrossRef Nilsson IL, Zedenius J, Li Y, Ekbom A (2007) The association between primary hyperparathyroidism and malignancy. Nationwide cohort analysis on cancer incidence after parathyroidectomy. Endocr Relat Cancer 14:1–7CrossRef
17.
go back to reference Sakai Y, Koizumi K, Sugitani I, Nakagawa K, Arai M, Utsunomiya J, Muto T, Fujita R, Kato Y (2002) Familial adenomatous polyposis associated with multiple endocrine neoplasia type 1-related tumors and thyroid carcinoma: a case report with clinicopathologic and molecular analyses. Am J Surg Pathol 26:103–110PubMedCrossRef Sakai Y, Koizumi K, Sugitani I, Nakagawa K, Arai M, Utsunomiya J, Muto T, Fujita R, Kato Y (2002) Familial adenomatous polyposis associated with multiple endocrine neoplasia type 1-related tumors and thyroid carcinoma: a case report with clinicopathologic and molecular analyses. Am J Surg Pathol 26:103–110PubMedCrossRef
18.
go back to reference Sener SF, Miller HH, DeCosse JJ (1984) The spectrum of polyposis. Surg Gynecol Obstet 159:525–532PubMed Sener SF, Miller HH, DeCosse JJ (1984) The spectrum of polyposis. Surg Gynecol Obstet 159:525–532PubMed
19.
go back to reference Haglund F, Andreasson A, Nilsson IL, Höög A, Larsson C, Juhlin CC (2010) Lack of S37A CTNNB1/β-catenin mutations in a Swedish cohort of 98 parathyroid adenomas. Clin Endocrinol (Oxf) 73:552–553 Haglund F, Andreasson A, Nilsson IL, Höög A, Larsson C, Juhlin CC (2010) Lack of S37A CTNNB1/β-catenin mutations in a Swedish cohort of 98 parathyroid adenomas. Clin Endocrinol (Oxf) 73:552–553
20.
go back to reference Miyoshi Y, Ando H, Nagase H, Nishisho I, Horii A, Miki Y, Mori T, Utsunomiya J, Baba S, Petersen G et al (1992) Germ-line mutations of the APC gene in 53 familial adenomatous polyposis patients. Proc Natl Acad Sci USA 89:4452–4456PubMedCrossRef Miyoshi Y, Ando H, Nagase H, Nishisho I, Horii A, Miki Y, Mori T, Utsunomiya J, Baba S, Petersen G et al (1992) Germ-line mutations of the APC gene in 53 familial adenomatous polyposis patients. Proc Natl Acad Sci USA 89:4452–4456PubMedCrossRef
21.
go back to reference Tominaga Y, Takagi H (1996) Molecular genetics of hyperparathyroid disease. Curr Opin Nephrol Hypertens 5:336–341PubMedCrossRef Tominaga Y, Takagi H (1996) Molecular genetics of hyperparathyroid disease. Curr Opin Nephrol Hypertens 5:336–341PubMedCrossRef
Metadata
Title
Molecular characterization of parathyroid tumors from two patients with hereditary colorectal cancer syndromes
Authors
Adam Andreasson
Luqman Sulaiman
Sónia do Vale
João Martin Martins
Florbela Ferreira
Gabriel Miltenberger-Miltenyi
Lucas Batista
Felix Haglund
Erik Björck
Inga-Lena Nilsson
Anders Höög
Catharina Larsson
C. Christofer Juhlin
Publication date
01-09-2012
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 3/2012
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-012-9520-z

Other articles of this Issue 3/2012

Familial Cancer 3/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine